NeOnc Technologies Secures Board Approval for $50 Million Strategic Partnership with Quazar Investment
Rhea-AI Summary
NeOnc Technologies (NASDAQ: NTHI) has secured board approval for a strategic $50 million partnership with Quazar Investment. The board unanimously approved the company's participation in the equity investment and MENA region expansion on June 30, 2025, marking the first of five required milestones.
The proposed structure includes a $25 per share pricing, with 70% of proceeds allocated to NeOnc common stock acquisition and 30% dedicated to clinical trials and infrastructure development in the UAE and MENA region. The company must complete remaining conditions within 120 days, including establishing NuroMENA and NuroCure in Abu Dhabi, executing licensing agreements for NEO100 and NEO212, and finalizing offering documents and business plans.
Positive
- Strategic $50 million investment commitment at $25 per share
- Geographic expansion into MENA region through new operational infrastructure
- Unanimous board approval signals strong internal support
- Development acceleration potential for core assets NEO100 and NEO212
Negative
- Transaction remains subject to multiple closing conditions within 120-day deadline
- Current agreement is based on non-binding term sheet
- Potential share dilution from new stock issuance
- Significant operational and regulatory hurdles in new geographic expansion
News Market Reaction
On the day this news was published, NTHI declined 18.05%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
CALABASAS, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced it has achieved a key milestone toward closing its previously announced strategic transaction with Quazar Investment: formal approval from NeOnc’s Board of Directors.
On June 30, 2025, NeOnc’s Board unanimously approved the company’s participation in the contemplated
“We are excited to report tangible progress in advancing our strategic partnership with Quazar Investment,” said Amir Heshmatpour, Executive Chairman & President of NeOnc Technologies Holdings, Inc. “The Board’s full support validates our shared vision for establishing a strong operational presence in the MENA region and accelerating clinical development of our core assets.”
Under the non-binding term sheet, Quazar intends to lead a capital formation round of up to
To complete the transaction, NeOnc must satisfy the remaining conditions within 120 days, including:
- Legal formation of NuroMENA and NuroCure in Abu Dhabi.
- Execution and transfer of a Sub-License Agreement from NeOnc to NuroCure, covering NEO100 and NEO212, pursuant to NeOnc’s license from USC Stevens Center for Innovation.
- Finalization of offering documents, including subscription agreements and a shareholder agreement.
- Approval of a comprehensive two-year business plan and budget, outlining operational and clinical milestones.
The closing remains subject to these conditions and the successful completion of the capital formation process.
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit neonc.com.
Important Cautions Regarding Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “plan,” “budget,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “evaluating,” or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information.
Examples of forward-looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated.
The “Risk Factors” section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds.
We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.
“NEO100” and NEO “212” are registered trademarks of NeOnc Technologies Holdings, Inc.
Company Contact:
info@neonc.com
Investor Contact:
James Carbonara
Hayden IR
(646)-755-7412
James@haydenir.com
FAQ
What is the value and share price of Quazar Investment's strategic partnership with NeOnc Technologies (NTHI)?
How will the $50 million investment in NeOnc Technologies (NTHI) be allocated?
What conditions must NeOnc Technologies (NTHI) meet to close the Quazar Investment deal?
What therapeutic areas does NeOnc Technologies (NTHI) focus on?
When did NeOnc Technologies' (NTHI) board approve the Quazar Investment partnership?
